Gene expression and prognosis of insulin‑like growth factor‑binding protein family members in non‑small cell lung cancer

Abstract

Lung cancer is the leading cause of cancer mortality worldwide. Approximately 85% of all lung cancer cases are classified as non-small cell lung cancer (NSCLC). Currently, there is no standard method to predict the survival of patients with NSCLC. Insulin-like growth factor-binding proteins (IGFBPs) function as modulators of IGF signaling and are attracting increasing attention for their role in NSCLC. However, the prognostic values of individual IGFBPs in NSCLC, particularly at the mRNA level, remain unknown. In the present study, the distinct expression patterns and prognostic values of IGFBP family members in patients with NSCLC through bioinformatics analysis were reported using a series of databases, including Gene Expression Profiling Interactive Analysis, Kaplan-Meier Plotter, cBioPortal, GeneMANIA, and the Database for Annotation, Visualization and Integrated Discovery. In patients with NSCLC, IGFBP2 and IGFBP3 were significantly upregulated, while IGFBP6 was downregulated. High IGFBP1/2/4 expression was correlated with poor overall survival (OS) in all NSCLC types, especially adenocarcinoma; however, high IGFBP2/5 expression was significantly correlated with favorable OS only in patients with squamous cell carcinoma. In addition, aberrant IGFBP1/2/3/4/5 mRNA levels were associated with the prognosis of subsets of NSCLC with different clinicopathological features. These results indicated that various IGFBPs can serve as useful prognostic biomarkers and as potential targets for NSCLC therapies.

Systematic construction and validation of an epithelial–mesenchymal transition risk model to predict prognosis of lung adenocarcinoma

“…Advances in chemotherapy, radiation therapy, and targeted therapy have reduced mortality among patients with LUAD over the years; however, the long-term survival rates have barely improved, especially compared with those of other cancers [ 5 ]. Thus, it is imperative to explore the molecular mechanisms of LUAD progression and develop better tumor prognostic markers that accurately predict the survival of patients with LUAD [ 6 , 7 ].…”

Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma

“…Delayed diagnosis, disease relapse, and drug resistance are common causes of mortality in LUAD patients [ 3 ]. Although several prognostic models have provided insights for therapeutic strategies in lung cancer [ 4 – 6 ], predictive and prognostic signatures are needed to accurately diagnose and treat LUAD as a heterogeneous and complex disease.…”

Levels of the IGF system components in malignant lesions of the lungs with preventive effect of 1,3-diethylbenzimidazolium triiodide in the experiment

“…Многочисленные эффекты IGF модулируют белки-переносчики, влияя на передачу их сигналов посредством секвестрации лигандов [15]. Суперсемейство IGFBP включает не менее 10 членов -6 традиционных (IGFBP1-6), которые связывают IGF с высокой аффинностью, и другие белки, которые связывают IGF с низкой аффинностью [15,16].…”

“…Участие IGFBP при злокачественной патологии варьирует в зависимости от типа злокачественности. Сравнительно недавно была продемонстрирована аномальная экспрессия IGFBP при немелкоклеточном раке легкого -у таких пациентов уровни IGF-I/IGFBP3 в сыворотке оказались значительно выше, чем у пациентов с гистологией мелкоклеточного рака [15]. Однако ни циркулирующий IGF-I, ни IGFBP3 не были связаны с клиническим исходом заболевания [18].…”